Frank Rimerman Advisors LLC Acquires 3,830 Shares of Novartis AG $NVS

Frank Rimerman Advisors LLC increased its holdings in shares of Novartis AG (NYSE:NVS) by 68.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 9,451 shares of the company’s stock after purchasing an additional 3,830 shares during the period. Frank Rimerman Advisors LLC’s holdings in Novartis were worth $1,212,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after buying an additional 2,666 shares during the period. AQR Capital Management LLC lifted its position in shares of Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after buying an additional 11,444 shares during the period. Empowered Funds LLC acquired a new stake in Novartis in the 1st quarter valued at $1,764,000. Sivia Capital Partners LLC grew its position in Novartis by 48.0% in the second quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares during the period. Finally, PFG Investments LLC raised its stake in Novartis by 3.8% during the second quarter. PFG Investments LLC now owns 3,050 shares of the company’s stock worth $369,000 after acquiring an additional 112 shares in the last quarter. 13.12% of the stock is owned by institutional investors.

Novartis Stock Down 0.1%

Shares of NVS opened at $148.71 on Friday. The business’s fifty day moving average price is $138.39 and its two-hundred day moving average price is $129.61. The firm has a market capitalization of $314.13 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.95 and a beta of 0.51. Novartis AG has a 52 week low of $97.71 and a 52 week high of $152.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.68 and a current ratio of 0.88.

Analyst Ratings Changes

Several research firms have recently weighed in on NVS. Bank of America raised shares of Novartis from a “neutral” rating to a “buy” rating in a report on Tuesday, November 25th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Novartis in a research note on Friday, January 16th. Citigroup assumed coverage on Novartis in a research report on Tuesday. They set a “buy” rating on the stock. TD Cowen reaffirmed a “hold” rating on shares of Novartis in a report on Monday, November 10th. Finally, Cfra Research upgraded Novartis to a “hold” rating in a report on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $119.75.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.